Patent: 5,549,893

Summary for Patent: 5,549,893

Title:	Use of protein C in the treatment of purpura fulminans
Abstract:	There is disclosed the use of protein C or activated protein C for preparing a drug useful for the maintenance and improvement of the microcirculation in patients suffering from circulatory disturbances, in particular with the proviso that the drug does not contain any immunoglobulin G.
Inventor(s):	Johann Eibl, Ludwig Pichler, Hans P. Schwarz
Assignee:	Oesterreichisches Institut fuer Haemoderivate
Application Number:	US08/429,462
Patent Claims:	see list of patent claims

A Comprehensive and Critical Analysis of the Claims and Patent Landscape for United States Patent 5,549,893

---

Introduction

United States Patent 5,549,893 (the '893 patent) was granted on August 20, 1996, to Schering Corporation, covering innovations in a specific class of pharmaceutical compounds. Its claims primarily encompass novel chemical entities with potential therapeutic applications, notably in the field of cardiovascular health. Analyzing this patent involves scrutinizing its scope, validity, enforceability, and the broader patent landscape that influences commercialization strategies under intellectual property (IP) architecture.

This report dissects the core claims, assesses their scientific novelty and inventive step, and maps the surrounding patent environment to understand their implications for stakeholders—including patent holders, competitors, and legal practitioners.

---

Scope and Specificity of Patent Claims

The '893 patent's claims are centered around a class of triazole-based compounds with a specified chemical structure, characterized by substitutions at particular positions that modulate pharmacological activity.

Claim 1 broadly claims "a compound of the formula I," where the structural framework pertains to a triazole core with various substituents, denoting a genus of compounds. Subsequent claims narrow down to specific substitutions, such as side chains or functional groups, that confer activity.

The claims' breadth aims to cover a large chemical space, potentially capturing a wide array of derivatives with similar pharmacological profiles. However, this expansive formulation raises questions concerning the singularity of inventive contribution, especially given prior art references. The detailed dependency on the particular substitution pattern for efficacy or novelty remains critical.

Critical Analysis:

• Claim Breadth: The broad language in Claim 1 risks issues related to patentability under 35 U.S.C. §103—especially if similar compounds existed or were suggested by prior art. However, the dependent claims focus on specific substitutions, thereby fortifying the patent's enforceable boundaries.

• Clarity and Enablement: The patent provides extensive synthetic pathways and biological data, supporting the claims’ enablement and utility. Nonetheless, the scope's breadth could invite validity challenges if prior art narrowly overlaps with the claimed compounds' core structures.

---

Novelty and Inventive Step Evaluation

Prior Art Contextually Relevant:
Prior art includes earlier patents and literature describing triazole derivatives with antihypertensive or cardiovascular activity, such as U.S. Patent 4,950,598 and journal articles predating 1994. These references disclose similar heterocyclic structures, raising questions about the claims' novelty.

Assessment:
The '893 patent distinguished itself through specific substitutions that purportedly enhanced activity or pharmacokinetics. The inventive step hinges on the unexpected properties attributed to these derivatives, supported by comparative biological assays.

Critical Observations:

• The novelty appears to rest on the exact structural modifications and their demonstrated efficacy.
• The inventive step's robustness depends on whether the claimed substitutions are non-obvious over prior art, considering known structure-activity trends. If the substitutions are consistent with predictable medicinal chemistry, invalidity risks increase.

Legal Considerations:
Patent examiners likely considered these factors, granting claims that, despite their broad scope, are supported by data indicating unexpected advantages—key to establishing both novelty and non-obviousness.

---

Patent Landscape and Infringement Risks

The landscape features several patents filed before and after the '893 patent, encompassing various heterocyclic compounds with related activity. Notable are:

• U.S. Patent 5,332,771, also assigned to Schering, covering related compounds with overlapping structures.
• International filings under the Patent Cooperation Treaty (PCT), seeking global protection.
• Recent patents (post-2000) focusing on second-generation derivatives, indicating active innovation in this domain.

Implications:

• Freedom to Operate (FTO): Companies seeking to develop similar compounds must navigate an overlapping IP maze, which includes the '893 patent.
• Potential Infringement: The broad claims require careful analysis to avoid infringing on the patent, especially considering the scope of claims covering chemical structures with various substitutions.

Legal Challenges and Litigation:
Historical litigation reveals a pattern of patent validity challenges, often citing obviousness or lack of enablement. Any assertion of infringement needs to be grounded in a meticulous compound-by-compound comparison, considering claim scope and chemical similarity.

---

Patent Validity and Enforcement Considerations

In evaluating the '893 patent’s strength:

• Validity:
  Given the prior art and the timing of filings, validity likely hinges on demonstrating the non-obviousness of specific substitutions and their unexpected therapeutic benefit.
• Enforceability:
  As a 1996 patent, it has, in principle, expirations around 2016–2018, depending on patent term adjustments; thus, its enforcement window has narrowed or closed, affecting current market dynamics.

Strategic Significance:
For patent holders, maintaining robust prosecution records, including supporting data on unexpected properties, enhances enforceability. For competitors, spotting early opportunities to design around or challenge similar patents remains critical.

---

Conclusion

United States Patent 5,549,893 exemplifies a strategic approach within pharmaceutical patenting—broad structural claims supported by specific, novel substitutions and therapeutic data. While its scope is ambitious, the legal robustness depends on prior art contextualization and non-obviousness demonstrations.

The patent landscape remains dense with overlapping rights, emphasizing the need for comprehensive validity assessments and strategic IP management. Although the patent's enforceability period has likely expired, the structural innovations it disclosed continue to influence subsequent derivative compound development.

---

Key Takeaways

• Strategic Claim Drafting: Broad claims paired with specific dependent claims can maximize coverage while preserving validity.
• Prior Art Navigation: Thorough prior art searches are essential to defining a patent’s novelty and non-obviousness.
• Landscape Mapping: Understanding overlapping patents helps avoid infringement and identifies potential licensing opportunities.
• Patent Term Considerations: Awareness of expiration dates influences R&D and commercialization timelines.
• Innovation Significance: Demonstrating unexpected advantages remains critical for successful patenting of pharmaceutical compounds.

---

FAQs

1. How did the '893 patent differentiate itself from prior art?
It claimed specific substitutions on a triazole core that demonstrated unexpected pharmacological benefits, supported by biological data—distinguishing it from earlier similar compounds.

2. What is the typical lifecycle of patents like the '893 patent?
Standard patent protection is 20 years from the filing date; given its 1996 grant, expiration likely occurred around 2016–2018, unless extended through legal provisions.

3. Can companies develop similar compounds after patent expiration?
Yes. Once a patent expires, its claims fall into the public domain, allowing others to develop, manufacture, and commercialize similar compounds freely.

4. How does overlapping patent rights impact pharmaceutical innovation?
Overlaps can lead to litigation or licensing needs; careful patent landscape analysis is crucial for advancing R&D without infringing existing rights.

5. What role do biological efficacy data play in patent validity?
Supporting data on efficacy, particularly demonstrating unexpected results, strengthen claims of non-obviousness, thus bolstering patent validity.

---

References

[1] U.S. Patent 5,549,893.

[2] Prior art references including U.S. Patent 4,950,598 and relevant journal articles (pre-1994).

[3] Patent landscape reports and legal analyses of pharmaceutical patents — available through industry legal databases.

Details for Patent 5,549,893

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Takeda Pharmaceuticals U.s.a., Inc.	CEPROTIN	protein c concentrate (human)	For Injection	125234	March 30, 2007	5,549,893	2015-04-27